TOR2A

Across TCGA pan-cancer cohorts, TOR2A Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TOR2A data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher TOR2A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TOR2A expression acts as an unfavorable survival marker.

BLCA and LUSC are the cancer types where TOR2A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.214	0.658	<.001	33	view →
LUSC	DFS	Median	All	0.174	0.645	.048	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

TOR2A–BLCA (OS)

Open the BLCA breakdown →